Pegliposomal Doxorubicin and 5-fluorouracil as Second Line Therapy for Metastatic Gastric Cancer

  • End date
    Dec 1, 2022
  • participants needed
  • sponsor
    Sixth Affiliated Hospital, Sun Yat-sen University
Updated on 24 January 2021
platelet count
renal function
neutrophil count
cancer chemotherapy
solid tumor
metastatic gastric cancer


For second-line chemotherapy for metastatic gastric cancer, single-agent irinotecan is the standard treatment. Anthracyclines are active but lack well designed investigations. The combination of epirubicin, fluorouracil and cisplatin (or oxaliplatin) are widely used in Europe. However, traditional anthracyclines are more cardiotoxic; and (Pegliposomal Doxorubicin) PLD, as a new liposome dosage form of doxorubicin, has better cardiac safety. Therefore, we designed this phase II trial with PLD and 5-Fu to compare irinotecan monotherapy in the second-line treatment.


Patients with metastatic gastric cancer failed to first-line therapy will be radomized to arm A with PLD and 5-Fu and arm B with irinotecan single agent therapy. Both regimens will be treated every 2 weeks until disease progression or untolerable toxicity. Efficacy will be assessed every 3 cycles and safety will be evaluated every cycle.

Condition Gastropathy, Gastric Cancer, Stomach Discomfort, Gastric Carcinoma, Stomach Cancer, gastric cancers
Treatment Irinotecan, 5Fluorouracil, DOXOrubicin Liposome Injection
Clinical Study IdentifierNCT04358341
SponsorSixth Affiliated Hospital, Sun Yat-sen University
Last Modified on24 January 2021


Yes No Not Sure

Inclusion Criteria

Age 18-70 years old
Metastatic gastric cancer progressed on first-line treatment
Expected survival time 3 months
At least one evaluable target lesion according to the solid tumor evaluation criteria (RECIST) version 1.1
Adequate bone marrow function reserve: white blood cell count 3.0 10 _9 / L, neutrophil count 1.5 10_ 9/ L; platelet count 100 109/ L; hemoglobin 90 g / L
Adequate liver and renal function reserve: AST and ALT 2.5 times the upper limit of normal value, total bilirubin 2 times the upper limit of normal value; serum creatinine 1.5 times the upper limit of normal value
LVEF 55 %
Be able to understand the research process, volunteer to participate in the study, and sign an informed consent form

Exclusion Criteria

Patients known to be allergic to active or other components of chemotherapeutic drugs
Patients who have been treated with PLD or irinotecan in the past
According to the researcher's judgment, other anti-tumor treatments such as radiotherapy and surgical resection are required during chemotherapy
Those who are not expected to be able to tolerate chemotherapy with severe heart disease or discomfort
d-MMR or MSI-H or Her-2 overexpression
Severe or uncontrolled infections or diabetes
History of other malignacis in the past 5 years (except for cured cervical carcinoma in situ or basal cell carcinoma of the skin)
Participated in other clinical trials within 4 weeks prior to the start of the study
Pregnant or lactating women, or women of childbearing age who refuse to take effective contraception during the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note